Mayo Clinic is teaming up with GE HealthCare on a first‑of‑its‑kind research study that could change how advanced prostate cancer is treated—and potentially help thousands of patients each year. The MI‑BET trial, launched from Mayo’s Rochester campus, aims to answer a simple but important question: Can doctors tailor radioligand therapy to each patient instead of using a one‑size‑fits‑all approach?
Radioligand therapy (RLT) is an emerging cancer treatment that works like a guided missile. Doctors use specialized imaging to find cancer cells, then deliver a targeted radioactive drug designed to attack those cells directly. Today, most patients receive a fixed number of treatment cycles, regardless of how their cancer responds along the way.
MI‑BET flips that model. Using GE HealthCare’s advanced StarGuide SPECT/CT scanner and MIM Software’s lesion‑tracking tools, Mayo researchers will closely monitor how tumors change during treatment. If imaging and blood‑based biomarkers show a patient is responding well, doctors may pause therapy rather than continue with additional cycles. That pause could reduce side effects, lower costs and free up treatment capacity for more patients.
“This is about making cancer care smarter,” Mayo leaders say in a news release. “If we can see earlier how a patient is responding, we can make better decisions and avoid unnecessary treatment.”
The study also explores whether new imaging biomarkers can help predict how a patient will respond before treatment even begins—an advance that could reshape precision oncology.
Beyond the science, MI‑BET is designed to broaden access. Mayo plans to use telemedicine, community partnerships and patient‑advocacy outreach to make participation easier for people who might otherwise face barriers.
For Minnesota, the collaboration underscores Mayo Clinic’s role as a global leader in medical innovation—and highlights how partnerships with companies like GE HealthCare can accelerate breakthroughs that benefit patients everywhere.
(Source here.)
